

# Are Patients' Perspectives Implemented in Clinical Trial Designs? A Literature Review and Semi-Structured Interviews to Explore Current Practices, Barriers, and Improvement Opportunities

Alice Vanneste<sup>1</sup>, Axelle Jankelevitch<sup>1</sup>, Peter Sinnaeve<sup>2,3</sup>, Isabelle Huys<sup>1</sup>, Tom Adriaenssens<sup>2,3</sup>

Contact: [alice.vanneste@kuleuven.be](mailto:alice.vanneste@kuleuven.be)

<sup>1</sup>Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

<sup>2</sup>Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium & <sup>3</sup>Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium

## Introduction

### Patient experience data (PED)

Patient-reported outcomes    Patient-reported experiences    Patient preferences    Patient input

↑ PED increasingly recognised by stakeholders as an important source of information that should be considered when making decisions

⚠ Challenges hamper the systematic implementation of PED in decision-making, including in clinical trials

## Objectives

This study aims to investigate current practices, barriers, and improvement opportunities regarding the implementation of **patients' perspectives into clinical trial designs**.

## Methods

### Literature review

Literature review with systematic search string in

- PubMed
- Embase

for reviews and guidelines on PED implementation in clinical trial design

Grey literature review of key regulatory and stakeholder guidance documents

### Qualitative interviews

Purposive sampling

Semi-structured interviews with key stakeholders, including physicians from Belgian hospitals (n=10)

Ad verbatim transcription

Thematic framework analysis

## Results\*

\* Based on preliminary insights


### BARRIERS

- Lack of guidelines and standardized methodologies
- Subjectivity of patient-reported outcome (PRO) data
- Cost and time constraints for collecting PED
- Patient burden and survey fatigue
- Representativeness of patient sample
- Lack of scientific knowledge of patients when giving input

### OPPORTUNITIES

- Development of disease-specific guidelines and PRO measures, and creation of core outcome sets
- Validation of patient-informed and patient-relevant endpoints
- Methodological guidance on patient-reported experience (PRE) measures and patient preferences (PP)
- Increased use of direct patient input

## FACILITATION OF MORE EFFECTIVE PED IMPLEMENTATION THROUGHOUT THE DRUG LIFE CYCLE



## Abbreviations

PED: Patient Experience Data, PRO: Patient Reported Outcome, PRE: Patient Reported Experience, PP: Patient Preferences

## Acknowledgements


This work is supported by the KU Leuven and partly supported by the internal KU Leuven funding C3/22/052.

Abstract of poster



## Conclusion

- Development of standards and disease-specific best practices
- Stimulate early involvement of patients in clinical trial designs
- Multi-stakeholder collaboration



Tailor decision-making to meet patients' needs and preferences for a more patient-centred healthcare system